Ultragenyx Pharmaceutical Inc. buy Royal Bank of Canada
Start price
26.09.24
/
50%
€49.00
Target price
26.09.25
€69.10
Performance (%)
-49.39%
End price
27.09.25
€24.80
Summary
This prediction ended on 27.09.25 with a price of €24.80. The BUY prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc. performed very badly with a performance of -49.39%. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 2.083% | 2.083% | -51.000% |
| iShares Core DAX® | -0,38 % | 2,61 % | 11,34 % |
| iShares Nasdaq 100 | -0,41 % | -2,00 % | 5,35 % |
| iShares Nikkei 225® | 1,84 % | 9,39 % | 33,53 % |
| iShares S&P 500 | -0,71 % | -0,48 % | 2,51 % |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€47.00
06.11.24
06.11.24
€71.64
06.11.25
06.11.25
-42.98%
07.11.25
07.11.25
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€41.20
22.04.24
22.04.24
€72.35
22.04.25
22.04.25
-22.82%
23.04.25
23.04.25